p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell, Blood Rev, vol.31, pp.251-260, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01493742
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy, Blood, vol.130, pp.1903-1913, 2017. ,
A high-risk, double-Hit, group of newly diagnosed myeloma identified by genomic analysis, Leukemia, 2018. ,
Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations, Sci Rep, vol.4, p.4223, 2014. ,
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis, Cell Death Differ, vol.20, pp.898-909, 2013. ,
Targeting mutant p53 for efficient cancer therapy, Nat Rev Cancer, vol.18, pp.89-102, 2018. ,
Role of Thiol Reactivity for Targeting Mutant p53, Cell Chem Biol, vol.25, 2018. ,
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis, vol.9, p.439, 2018. ,
DOI : 10.1101/214049
URL : https://www.biorxiv.org/content/biorxiv/early/2017/11/05/214049.full.pdf
Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway, BMC Cancer, vol.14, p.437, 2014. ,
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, pp.1626-1662, 2014. ,
CRISPR-Cas9-based target validation for p53-reactivating model compounds, Nat Chem Biol, vol.12, pp.22-30, 2016. ,
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain, Cancer Cell, vol.15, pp.376-88, 2009. ,
Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation, Nat Commun, vol.8, p.14844, 2017. ,
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase, Cell Death Dis, vol.4, p.881, 2013. ,
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, pp.285-293, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02100586
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-82, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00550232
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways, J Hematol Oncol, vol.11, p.137, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01958772
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, pp.1973-1979, 2010. ,
p53 regulates CD46 expression and measles virus infection in myeloma cells, Blood Adv, vol.2, pp.3492-505, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01957487
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.72, pp.4562-73, 2012. ,
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment, Blood, vol.132, pp.2656-69, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01900681
Elimination of stemlike cancer cell side-population by auranofin through modulation of ROS and glycolysis, Cell Death Dis, vol.9, p.89, 2018. ,
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, vol.179, pp.684-692, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01353369
Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma, Mol Cancer Ther, vol.17, pp.2156-63, 2018. ,
DOI : 10.1158/1535-7163.mct-17-1173